Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

By prioritising local production of essential pharmaceuticals, the government seeks not only to secure the healthcare needs ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health ...

The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, ...

Maryland’s biotech industry plays a pivotal role in advancing global health initiatives. This vibrant sector is characterized ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...